Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study

BACKGROUND: MET amplification is associated with acquired resistance to first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in treating non-small-cell lung cancer (NSCLC); however, the therapeutic strategy in these patients is undefined. Herein we report the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenxian, Wang, Hong, Lu, Peihua, Yu, Zongyang, Xu, Chunwei, Zhuang, Wu, Song, Zhengbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385446/
https://www.ncbi.nlm.nih.gov/pubmed/30791921
http://dx.doi.org/10.1186/s12967-019-1803-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385446/
https://www.ncbi.nlm.nih.gov/pubmed/30791921
http://dx.doi.org/10.1186/s12967-019-1803-9

Ejemplares similares